Australian scientists have discovered how the immune system can control melanoma, a mechanism which could be used to enhance cancer treatments.
Published today in Nature, Peter Doherty Institute for Infection and Immunity (Doherty Institute) and Telethon Kids Institute researchers investigated the role of a particular immune cell, tissue-resident memory T (TRM) cells, in controlling melanoma.
TRM cells were able to control the tumour in the mice for the life of the animal, which is likely to equate to decades of protection in humans.
University of Melbourne PhD student, Simone Park from the Doherty Institute, created an imaging model to study TRM cells’ and melanoma in a mouse model.
“Using a special microscope, we could see individual melanoma cells sitting in the skin of the mouse, and could watch the T cells move through the skin, find the melanoma cells and control the growth of those cells,” Ms Park explained.
One of the main issues for cancer patients is that there is always a risk that the tumour can come back years later, after surgery or chemotherapy.
Previous research has shown that small numbers of cancer cells persist in the body after treatment and that the immune system probably keeps the cancer cells under control but this study in mice could study the immune system directly. This is work that could never be done in people.
“I was able to see through moving images that these TRM cells are important for maintaining the control of the tumour cells; if you remove the TRM cells you have a break in that control and the cancer can start to grow back again,” Ms Park said.
“If you could make more of these TRM cells through immunotherapies, or enhance the activity of those that are already there in some way, you could boost anti-tumour immunity.”
Senior author on the paper, University of Melbourne Associate Professor Thomas Gebhardt, Laboratory Head at the Doherty Institute, said an increase of TRM cells has already been associated with better outcomes in cancer patients, but the way they work to suppress tumours has remained unknown.
“The principal of cutting-edge immunotherapies currently in clinical practise is that they generate a T-cell response. But if we can hone in on one type of T-cell – the TRM cells specifically, we could have an even bigger impact on stopping cancers from coming back,” Associate Professor Gebhardt said.
“We now have a much better understanding of which T-cells are important in controlling skin cancers and how those cells are working but there is still much more work to do to make these cells work even better,” Associate Professor Gebhardt said.
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- Sharp declines in melanoma mortality 'unprecedented in cancer medicine'on March 20, 2020 at 11:23 am
The introduction and approval of new treatments for metastatic melanoma has led to significant declines in population-level mortality over the past several years, according to results of a ...
- Large decrease seen in melanoma mortality from 2013 to 2016on March 20, 2020 at 8:01 am
(HealthDay)—From 2013 to 2016, there was a large decrease of 17.9 percent in melanoma mortality, according to a study published online March 19 in the American Journal of Public Health. Juliana ...
- New melanoma treatments reduce deaths from skin canceron March 20, 2020 at 12:49 am
New treatments for melanoma have dramatically reduced deaths from this often fatal skin cancer. Leaders of a new study report that the death rate from aggressive melanoma that spread to other organs ...
- U.S. Sees Big Drop in Deaths From Melanomaon March 19, 2020 at 2:03 pm
THURSDAY, March 19, 2020 (HealthDay News) -- New treatments for melanoma have dramatically reduced deaths from this often fatal skin cancer. Leaders of a new study report that the death rate from ...
- Melanoma Isn't as Deadly as It Used to Beon March 19, 2020 at 1:59 pm
100% of the fees we collect are used to support our nonprofit mission. Learn more. Between 2013 and 2016, the mortality rate for melanoma declined by almost 18 percent, despite continued increases in ...
- Melanoma is killing fewest Americans in decadeson March 19, 2020 at 1:00 pm
Advances in treatment have led to the largest yearly declines in deaths due to melanoma ever recorded for this skin cancer, results of a new study suggest. Led by researchers at NYU Grossman School of ...
- Melanoma Cancer Market With Robust CAGR in Forecast Period 2020 to 2026on March 19, 2020 at 3:54 am
Melanoma Cancer is a skin cancer that develops due to expose of UV rays on the skin. Increasing incidence of melanoma across the globe and rising ozone layer depletion due to global warming are the ...
- 2019 Analysis of the Global Melanoma Treatment Market - ResearchAndMarkets.comon March 19, 2020 at 2:55 am
DUBLIN--(BUSINESS WIRE)--The "Global Melanoma Treatment Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering. The Melanoma Treatment market is expected to reach $9.70 ...
- The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patientson March 18, 2020 at 7:47 am
Modern advances in technology such as next-generation sequencing and digital PCR make detection of minor circulating cell-free tumor DNA amounts in blood from cancer patients possible. Samples can be ...
- OncoSec Announces Publication of Positive TAVO™ Monotherapy Results in Metastatic Melanoma Patients in Annals of Oncologyon March 17, 2020 at 5:30 am
SAN DIEGO and PENNINGTON, N.J., March 17, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer ...
via Bing News